You can buy or sell CLVS and other stocks, options, ETFs, and crypto commission-free!
Clovis Oncology, Inc. Common Stock, also called Clovis Oncology, is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Read More Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
52 Week High
52 Week Low
Clovis Oncology Announces Presentations at 2019 AACR Annual Meeting
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six abstracts highlighting progress in the Rubraca clinical development and lucitanib preclinical research programs will be presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting taking place March 29 – April 3 in Atlanta. The accepted abstracts summarize multiple clinical trials and nonclinical research in which Rubraca is being studied as single agent and combination therapy in a varie...
Markets InsiderMar 16
Clovis Oncology to Highlight Rubraca® (rucaparib) Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that data from post hoc exploratory analyses from the ARIEL3 Phase 3 clinical study of Rubraca will be presented during oral plenary and poster sessions at the Society of Gynecologic Oncology 2019 Congress (SGO), March 16 -19, 2019 in Honolulu, Hawaii. Data to be presented will highlight ARIEL3 results in different patient demographics, including age and deleterious germline mutation status. "The results from these post hoc analyses of the ARIEL3 study d...
Expected May 7, Pre-Market